대사성 의약품 시장 : 치료법별, 용도별, 유통 채널별, 지역별

Metabolism Drugs Market is estimated to be valued at USD 14.8 Bn in 2026 and is expected to reach USD 18.21 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.

Metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are meant to. Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease.

Market Dynamics

Increasing inorganic growth activities such as collaborations and agreement among market players is expected to drive the market growth over the forecast period. For instance, on December 10, 2021, Eli Lilly and Company, a pharmaceutical company and Regor Therapeutics Group, a biotechnology company announced multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. According to this agreement, Eli Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan.

Furthermore, market players are increasingly focusing on clinical trials for development of enzyme replacement therapy. For instance, on June 16, 2020, Sanofi, a global biopharmaceutical company announced the results for investigational enzyme replacement therapy (ERT), avalglucosidase alfa that showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD), according to results from the Phase 3 trial. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD.

Key features of the study

• This report provides an in-depth analysis of the global metabolism drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global metabolism drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global metabolism drugs market

Market Segmentation

• By Therapy Type
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
  • Small Molecule Drugs
  • Others
• By Application
  • Glycogen Metabolism Disease
  • Lipid Metabolism Disease
  • Amino Acid Metabolism Disease
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Merck & Co., Inc.
  • Novartis AG
  • Amicus Therapeutics
  • AstraZeneca Plc
  • Boehringer Ingelheim
  • Shire Plc
  • Sanofi Genzyme
  • BioMarin Pharmaceutical, Inc.
  • Horizon Pharma Plc
  • GlaxoSmithKline Plc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Therapy Type
  • Market Snippet, By Application
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • PEST Analysis
  • PORTER's Five Forces Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global Metabolism Drugs Market, By Therapy Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Enzyme Replacement Therapy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Substrate Reduction Therapy
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Small Molecule Drugs
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Metabolism Drugs Market, By Application, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Glycogen Metabolism Disease
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Lipid Metabolism Disease
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Amino Acid Metabolism Disease
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Metabolism Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Online Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Metabolism Drugs Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis (3x3 Matrix)
• Company Profiles
  • Merck & Co., Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Novartis AG
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Amicus Therapeutics
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • AstraZeneca Plc
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Boehringer Ingelheim
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Shire Plc
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Sanofi Genzyme
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • BioMarin Pharmaceutical, Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Horizon Pharma Plc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. Section

• References
• Research Methodology
• About Us and Sales Contact